What changed
Revenue grew 13.5% to NZ$1,899.3m, with the China and Other Asia segment the clear driver, lifting NZ$158.9m to NZ$1,302.0m and maintaining a roughly 68% share of group sales. Australia and New Zealand was effectively flat at NZ$316.0m, shrinking as a mix contributor. The USA grew to NZ$139.3m and Mataura Valley Milk (MVM) expanded meaningfully to NZ$194.9m, though both remain EBITDA-loss-making.
EBITDA rose 17.1% to NZ$274.3m, with the China and Other Asia segment carrying most of the uplift. PBT grew 21.5% to NZ$289.3m — the cleaner operating read, given that the effective tax rate eased modestly to 33.6% from 35.4%. NPAT followed at NZ$202.9m, up 21.1%.
Operating cash flow deteriorated to NZ$201.5m from NZ$255.7m, even as EBITDA rose, compressing the OCF/EBITDA conversion ratio from 109% to 73%. Capex was unusually light at NZ$3.7m (0.2% of revenue) versus NZ$17.0m the prior year. The balance sheet strengthened: cash increased to NZ$1.10b, leaving a net cash position of approximately NZ$1.02b. Gross borrowings rose to NZ$77.8m, reflecting a NZ$38.8m related-party loan tied to MVM's non-controlling shareholder and NZ$39.0m in bank debt.
FY25 also marked the first-ever dividends: 20.0 cents per share in total for the year, of which the current announcement component is 11.5 cents per share.
What matters
-
Cash conversion deterioration is the most significant quality flag. OCF fell NZ$54.3m despite a NZ$40.0m EBITDA gain. Inventory did decline to NZ$139.1m from NZ$179.6m, which would normally support cash conversion — meaning the drag likely sits in receivables or other working capital movements not separately disclosed. Without receivable days or a full working capital bridge, the source of this compression cannot be fully explained from the supplied data. An OCF/EBITDA ratio of 73% is a meaningful step down from what had been a cash-generative model.
-
China and Other Asia concentration is increasing, not diversifying. The segment held 68.4% of group revenue and contributed NZ$332.4m of segment EBITDA against a combined NZ$24.3m loss from the USA and MVM. The strategic rationale for the USA and MVM is apparent, but at present the group's earnings quality is almost entirely a function of one geographic market operating in a shrinking infant formula category. The release cites record China-label IMF market share and double-digit English-label growth, both of which matter for durability but also carry channel and regulatory risk.
-
The supply-chain transformation and MVM investment are at an inflection point. The release references "major updates that substantially progress its supply chain transformation strategy," and MVM revenue grew 42.8% to NZ$194.9m while narrowing its EBITDA loss to NZ$15.0m from NZ$20.5m. Whether this capital deployment generates a positive return, and on what timeline, will materially affect whether the large net cash balance is working productively or simply accumulating.
Expectations
No numeric FY26 targets were provided in the supplied extracts; the release references a qualitative FY26 outlook only. The prior period's guidance had been upgraded at the HY25 mark, and the full-year result appears to have been delivered broadly in line with that upgraded guidance.
The half-year shape reveals meaningful second-half weighting: HY25 contributed only 43.3% of full-year EBITDA and 45.2% of NPAT, with the implied second half delivering NZ$155.5m EBITDA and NZ$111.2m NPAT. This pattern is consistent with the daigou and cross-border e-commerce channels in China, where Q4 calendar-year purchasing often concentrates. Any investor extrapolating the second-half run rate should account for this seasonality.
English-label IMF growth is explicitly framed as a recovery from "several periods of decline," which means the FY25 result benefits from a favourable prior-period base in that channel. Whether that recovery is structural or base-effect-driven is not resolvable from the filing alone.
The inaugural dividend of 20.0 cents per share total for FY25, with a payout ratio of roughly 71% of NPAT, signals that management considers the earnings base sufficiently durable to commit to shareholder returns. At NZ$197.8m pre-lease free cash flow, the dividend appears covered, but the NZ$1.0b-plus net cash position suggests the distribution policy is still conservative relative to balance-sheet capacity.
Quality of result
The PBT and NPAT growth at 21.5% and 21.1% respectively look broadly genuine at the headline level. There are no disclosed non-recurring gains, no discontinued operations, and the tax effect is minor. Inventory destocking has improved balance-sheet efficiency.
However, three factors qualify the durability assessment. First, OCF/EBITDA conversion dropping to 73% suggests either revenue that has been recognised ahead of cash collection, or other working capital build that partially offset the inventory release — the data does not support a clean explanation. Second, capex at 0.2% of revenue is abnormally low; the supply-chain transformation referenced prominently in the release implies that capital spending will need to step up, meaning current free cash flow is temporarily elevated relative to a normalised investment rate. Third, English-label IMF double-digit growth explicitly laps a period of weakness, so the year-on-year rate is likely to moderate as the base normalises.
The China and Other Asia margin — inferred at roughly 25.5% — appears genuinely strong, and record China-label market share in a contracting market is a real achievement. But that single segment is also the single earnings concentration risk.
Unresolved
- The working capital bridge is opaque: receivables are not separately disclosed, so the reason operating cash flow fell NZ$54.3m while EBITDA rose NZ$40.0m cannot be fully explained. The inventory release should have supported cash conversion, not undermined it.
- The MVM non-controlling shareholder loan of NZ$38.8m is a related-party obligation; the terms, security, and repayment timeline are not clear from the supplied extracts, and its interaction with the "supply chain transformation" announcement needs clarification.
- The qualitative FY26 outlook referenced in the release was not reproduced in the supplied extracts, so whether management has framed revenue or margin expectations for the coming year — and what assumptions about the China IMF market underpin them — is unknown.
- English-label IMF growth is cycling a weak prior period; the degree to which FY26 growth can sustain double digits as the base normalises is unresolved.
- The supply-chain transformation capital commitment has not been quantified from the supplied data, leaving the future capex profile and its impact on free cash flow generation uncertain.
This briefing cannot assess the competitive or regulatory trajectory of the China infant formula market, including any forthcoming registration cycle changes that could affect a2MC's channel or product access.
Key metrics
| Metric | FY25 | FY24 | Change |
|---|---|---|---|
| Revenue | $1899.3m | $1.7m | +113403.1% ↑ |
| EBITDA | $274.3m | $0.2m | +116970.6% ↑ |
| Net profit after tax | $202.9m | $0.2m | +120972.1% ↑ |
| Net cash inflow from operating activities | $201.5m | $0.3m | +78680.7% ↑ |
| Final dividend per share | 11.5c | — | — |
| Operating profit | $248.1m | $0.2m | +122571.0% ↑ |
| Profit before tax | $289.3m | $0.2m | +121363.0% ↑ |
| Cash and cash equivalents | $1100.2m | $1.0m | +113443.4% ↑ |
| Total assets | $1942.1m | $1.7m | +111845.3% ↑ |
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| China and Other Asia | $1302.0m | $1143.1m | $332.4m | +0.2pp |
| Australia and New Zealand | $316.0m | $317.3m | $57.5m | -2.3pp |
| USA | $139.3m | $113.7m | −$9.3m | +0.5pp |
| Mataura Valley Milk | $194.9m | $136.4m | −$15.0m | +2.1pp |
Analytical metrics
| Metric | FY25 | FY24 | Context |
|---|---|---|---|
| PBT growth | +21.5% | — | cleaner earnings measure |
| Effective tax rate | 33.6% | 35.4% | — |
| OCF / EBITDA (cash conversion) | 73.5% | 109.1% | deteriorated |
| FCF pre-lease | $197.8m | $238.7m | −$40.9m |
| FCF / NPAT | 97.5% | 142.4% | complementary conversion metric |
| Capex % revenue | 0.2% | 1.0% | — |
| Capex | −$3.7m | $17.0m | −$20.7m |
| Net debt | −$1022.4m | −$931.1m | −$91.4m |
| Net debt / EBITDA | -3.73x | -3.97x | Strengthening |
| Gross borrowings | $77.8m | $37.9m | +$39.9m |
| Payout ratio vs NPAT | 71.3% | — | — |
| Payout ratio vs FCF pre-lease | 73.2% | — | covered |
| ROE (annualised) | 14.2% | 13.3% | Strengthening |
| HY25 share of FY25 revenue | 47.0% | — | Other half was 53.0% |
| HY25 share of FY25 EBITDA | 43.3% | — | Other half was 56.7% |
| HY25 share of FY25 NPAT | 45.2% | — | Other half was 54.8% |
| Profit from continuing operations | $202.9m | — | — |
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.